Influence of γ-secretase inhibition by DAPT on human cellularity and cell number of human subpopulations after 28 days of FTOC seeded with human CD34+Lin- cord blood progenitor cells
. | . | DAPT treatment . | . | . | ||
|---|---|---|---|---|---|---|
| Cell type . | Control, no. cells . | 2 μM, no. cells . | 5 μM, no. cells . | 10 μM, no. cells . | ||
| Human cells | 55 645 ± 8 676 | 41 591 ± 6 869 | 24 541 ± 3 191* | 32 089 ± 1 755 | ||
| CD34+ | 5 618 ± 1 469 | 1 792 ± 736* | 1 411 ± 110* | 1 930 ± 188 | ||
| CD7+ | 50 646 ± 8 137 | 27 448 ± 9 725* | 8 531 ± 2 563* | 4 533 ± 1 060* | ||
| CD4ISP | 24 828 ± 3 974 | 18 487 ± 4 598 | 915 ± 596* | 0 ± 0* | ||
| DP | 8 562 ± 3 238 | 2 549 ± 951 | 345 ± 173* | 0 ± 0* | ||
| IC CD3+ | 53 119 ± 8 319 | 35 414 ± 6 671 | 5 333 ± 1 856* | 518 ± 326* | ||
| IC TCR-β | 14 103 ± 3 490 | 344 ± 210* | 25 ± 25* | 0 ± 0* | ||
| CD3+ | 10 952 ± 5 146 | 1 474 ± 737* | 21 ± 21* | 0 ± 0* | ||
| TCR-αβ | 8 449 ± 2 740 | 291 ± 212* | 0 ± 0* | 0 ± 0* | ||
| TCR-γδ | 2 479 ± 313 | 294 ± 114* | 0 ± 0* | 0 ± 0* | ||
| CD4+HLA-DR+ | 1 614 ± 266 | 1 391 ± 496 | 2 640 ± 502 | 5 266 ± 790* | ||
| CD14+ | 231 ± 75 | 241 ± 60 | 533 ± 107* | 1 352 ± 356* | ||
| CD56+ | 1 247 ± 656 | 2 052 ± 379 | 4 324 ± 1 134* | 3 079 ± 861 | ||
| CD19+ | 38 ± 45 | 454 ± 171* | 6 516 ± 2 219* | 17 357 ± 3 052* | ||
. | . | DAPT treatment . | . | . | ||
|---|---|---|---|---|---|---|
| Cell type . | Control, no. cells . | 2 μM, no. cells . | 5 μM, no. cells . | 10 μM, no. cells . | ||
| Human cells | 55 645 ± 8 676 | 41 591 ± 6 869 | 24 541 ± 3 191* | 32 089 ± 1 755 | ||
| CD34+ | 5 618 ± 1 469 | 1 792 ± 736* | 1 411 ± 110* | 1 930 ± 188 | ||
| CD7+ | 50 646 ± 8 137 | 27 448 ± 9 725* | 8 531 ± 2 563* | 4 533 ± 1 060* | ||
| CD4ISP | 24 828 ± 3 974 | 18 487 ± 4 598 | 915 ± 596* | 0 ± 0* | ||
| DP | 8 562 ± 3 238 | 2 549 ± 951 | 345 ± 173* | 0 ± 0* | ||
| IC CD3+ | 53 119 ± 8 319 | 35 414 ± 6 671 | 5 333 ± 1 856* | 518 ± 326* | ||
| IC TCR-β | 14 103 ± 3 490 | 344 ± 210* | 25 ± 25* | 0 ± 0* | ||
| CD3+ | 10 952 ± 5 146 | 1 474 ± 737* | 21 ± 21* | 0 ± 0* | ||
| TCR-αβ | 8 449 ± 2 740 | 291 ± 212* | 0 ± 0* | 0 ± 0* | ||
| TCR-γδ | 2 479 ± 313 | 294 ± 114* | 0 ± 0* | 0 ± 0* | ||
| CD4+HLA-DR+ | 1 614 ± 266 | 1 391 ± 496 | 2 640 ± 502 | 5 266 ± 790* | ||
| CD14+ | 231 ± 75 | 241 ± 60 | 533 ± 107* | 1 352 ± 356* | ||
| CD56+ | 1 247 ± 656 | 2 052 ± 379 | 4 324 ± 1 134* | 3 079 ± 861 | ||
| CD19+ | 38 ± 45 | 454 ± 171* | 6 516 ± 2 219* | 17 357 ± 3 052* | ||
Results represent mean ± SEM of 4 independent experiments.
Significant difference (P < .05; paired Student t test) compared with the vehicle-treated control cultures